{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:02:52Z","timestamp":1792029772243,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province","award":["CXPJJH122003-41"],"award-info":[{"award-number":["CXPJJH122003-41"]}]},{"name":"Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province","award":["CXPJJH122003-41"],"award-info":[{"award-number":["CXPJJH122003-41"]}]},{"name":"Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province","award":["CXPJJH122003-41"],"award-info":[{"award-number":["CXPJJH122003-41"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-025-01897-2","type":"journal-article","created":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T05:59:05Z","timestamp":1754114345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Proteinuria reduction by and safety of finerenone in Chinese patients with CKD without diabetes: a real-world retrospective study"],"prefix":"10.1186","volume":"25","author":[{"given":"Guangting","family":"Cong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manshu","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,2]]},"reference":[{"key":"1897_CR1","unstructured":"G. B. D. Chronic kidney disease collaboration. global, regional, and National burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020; 395:709\u201333."},{"key":"1897_CR2","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","volume":"158","author":"PE Stevens","year":"2013","unstructured":"Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group M. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825\u201330.","journal-title":"Ann Intern Med"},{"key":"1897_CR3","doi-asserted-by":"publisher","first-page":"A7","DOI":"10.1053\/j.ajkd.2016.12.004","volume":"69","author":"R Saran","year":"2017","unstructured":"Saran R, Robinson B, Abbott KC, Agodoa LY, Albertus P, Ayanian J, et al. Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2017;69:A7-8 US Renal Data System 2016 Annual Data Report:","journal-title":"Am J Kidney Dis."},{"key":"1897_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","volume":"382","author":"V Jha","year":"2013","unstructured":"Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260\u201372.","journal-title":"Lancet"},{"key":"1897_CR5","unstructured":"Organization WH. The top 10 causes of death. World Health Organization. 2020."},{"key":"1897_CR6","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1681\/ASN.2012040392","volume":"24","author":"AA Honeycutt","year":"2013","unstructured":"Honeycutt AA, Segel JE, Zhuo X, Hoerger TJ, Imai K, Williams D. Medical costs of CKD in the medicare population. J Am Soc Nephrol. 2013;24:1478\u201383.","journal-title":"J Am Soc Nephrol"},{"key":"1897_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2471\/BLT.07.041715","volume":"86","author":"SL White","year":"2008","unstructured":"White SL, Chadban SJ, Jan S, Chapman JR, Cass A. How can we achieve global equity in provision of renal replacement therapy? Bull World Health Organ. 2008;86:229\u201337.","journal-title":"Bull World Health Organ"},{"key":"1897_CR8","first-page":"S1","volume":"19","author":"S Naicker","year":"2009","unstructured":"Naicker S. End-stage renal disease in sub-Saharan Africa. Ethn Dis. 2009;19:S1\u201313.","journal-title":"Ethn Dis"},{"key":"1897_CR9","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296\u2013305.","journal-title":"N Engl J Med"},{"key":"1897_CR10","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1681\/ASN.2005101085","volume":"17","author":"M Tonelli","year":"2006","unstructured":"Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006;17:2034\u201347.","journal-title":"J Am Soc Nephrol"},{"key":"1897_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.pop.2008.01.008","volume":"35","author":"R Thomas","year":"2008","unstructured":"Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Prim Care. 2008;35:329\u201344. vii.","journal-title":"Prim Care"},{"key":"1897_CR12","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","volume":"398","author":"K Kalantar-Zadeh","year":"2021","unstructured":"Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021;398:786\u2013802.","journal-title":"Lancet"},{"key":"1897_CR13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/01.mnh.0000444822.25991.f6","volume":"23","author":"DC Crews","year":"2014","unstructured":"Crews DC, Liu Y, Boulware LE. Disparities in the burden, outcomes, and care of chronic kidney disease. Curr Opin Nephrol Hypertens. 2014;23:298\u2013305.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1897_CR14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1001\/jama.2015.0602","volume":"313","author":"AS Levey","year":"2015","unstructured":"Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA. 2015;313:837\u201346.","journal-title":"JAMA"},{"key":"1897_CR15","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"Kidney Disease","year":"2021","unstructured":"Kidney Disease. Improving global outcomes glomerular diseases work G. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100:S1\u2013276.","journal-title":"Kidney Int"},{"key":"1897_CR16","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1681\/ASN.2014070714","volume":"26","author":"S Thompson","year":"2015","unstructured":"Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S, et al. Cause of death in patients with reduced kidney function. J Am Soc Nephrol. 2015;26:2504\u201311.","journal-title":"J Am Soc Nephrol"},{"key":"1897_CR17","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752\u201372.","journal-title":"Circulation"},{"key":"1897_CR18","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252\u201363.","journal-title":"N Engl J Med"},{"key":"1897_CR19","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","volume":"145","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL, et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022;145:437\u201347.","journal-title":"Circulation"},{"key":"1897_CR20","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","volume":"375","author":"CKD Prognosis","year":"2010","unstructured":"Prognosis CKD, Matsushita C, van der Velde K, Astor M, Woodward BC, Levey M. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073\u201381.","journal-title":"Lancet"},{"key":"1897_CR21","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial. JAMA. 2015;314:884\u201394.","journal-title":"JAMA"},{"key":"1897_CR22","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"key":"1897_CR23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42:152\u201361.","journal-title":"Eur Heart J"},{"key":"1897_CR24","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"1897_CR25","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341:709\u201317.","journal-title":"N Engl J Med"},{"key":"1897_CR26","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1\u201359. https:\/\/doi.org\/10.1016\/j.kisu.2017.04.001.","DOI":"10.1016\/j.kisu.2017.04.001"},{"key":"1897_CR27","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","volume":"143","author":"G Filippatos","year":"2021","unstructured":"Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation. 2021;143:540\u201352.","journal-title":"Circulation"},{"key":"1897_CR28","doi-asserted-by":"crossref","unstructured":"Dialsingh I. Applied Longitudinal Analysis by G. M. Fitzmaurice, N. M. Laird and J. H. Ware. Journal of the Royal Statistical Society Series A: Statistics in Society. 2007;170(1):253,.","DOI":"10.1111\/j.1467-985X.2006.00455_4.x"},{"key":"1897_CR29","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","volume":"96","author":"J Barrera-Chimal","year":"2019","unstructured":"Barrera-Chimal J, Girerd S, Jaisser F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney Int. 2019;96:302\u201319.","journal-title":"Kidney Int"},{"key":"1897_CR30","doi-asserted-by":"publisher","unstructured":"Jerome JR, Deliyanti D, Suphapimol V, Kolkhof P, Wilkinson-Berka JL. Finerenone, a Non-Steroidal mineralocorticoid receptor antagonist, reduces vascular injury and increases regulatory T-Cells: studies in rodents with diabetic and neovascular retinopathy. Int J Mol Sci. 2023;24. https:\/\/doi.org\/10.3390\/ijms24032334.","DOI":"10.3390\/ijms24032334"},{"key":"1897_CR31","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1053\/j.ackd.2021.09.010","volume":"28","author":"SB Nicholas","year":"2021","unstructured":"Nicholas SB. Novel Anti-inflammatory and Anti-fibrotic agents for diabetic kidney Disease-From bench to bedside. Adv Chronic Kidney Dis. 2021;28:378\u201390.","journal-title":"Adv Chronic Kidney Dis"},{"key":"1897_CR32","doi-asserted-by":"crossref","unstructured":"Theofilis P, Vordoni A, Kalaitzidis RG. Oxidative Stress Management in Cardiorenal Diseases: Focus on Novel Antidiabetic Agents, Finerenone, and Melatonin. Life (Basel). 2022;12.","DOI":"10.3390\/life12101663"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01897-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-01897-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01897-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T11:43:51Z","timestamp":1757331831000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-025-01897-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,2]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1897"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-01897-2","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,2]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Given the retrospective nature of this study, the institutional review board waived the requirement for informed consent; however, they provided a comprehensive ethical review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"189"}}